C-Rad 将来の成長

Future 基準チェック /56

C-Rad利益と収益がそれぞれ年間34.7%と14.8%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に24.5% 34.8%なると予測されています。

主要情報

34.7%

収益成長率

34.8%

EPS成長率

Medical Equipment 収益成長	22.5%
収益成長率	14.8%
将来の株主資本利益率	24.5%
アナリストカバレッジ	Low
最終更新日	22 Nov 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

LSE:0R44 - アナリストの将来予測と過去の財務データ ( )SEK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	679	121	87	N/A	1
12/31/2025	598	89	60	N/A	1
12/31/2024	517	61	46	N/A	1
9/30/2024	486	58	38	48	N/A
6/30/2024	497	54	68	81	N/A
3/31/2024	458	48	47	62	N/A
12/31/2023	425	36	16	33	N/A
9/30/2023	385	24	-3	14	N/A
6/30/2023	357	20	-27	-13	N/A
3/31/2023	329	12	-11	3	N/A
12/31/2022	301	7	-2	10	N/A
9/30/2022	280	14	-16	-9	N/A
6/30/2022	260	12	-6	1	N/A
3/31/2022	257	21	6	12	N/A
12/31/2021	261	25	12	18	N/A
9/30/2021	258	26	16	23	N/A
6/30/2021	247	25	30	36	N/A
3/31/2021	230	17	26	32	N/A
12/31/2020	222	14	12	18	N/A
9/30/2020	198	-11	2	9	N/A
6/30/2020	201	-16	-13	-4	N/A
3/31/2020	210	-14	-19	-7	N/A
12/31/2019	205	-14	5	16	N/A
9/30/2019	212	23	-4	5	N/A
6/30/2019	203	24	7	14	N/A
3/31/2019	204	27	9	13	N/A
12/31/2018	190	21	-14	-10	N/A
9/30/2018	174	-2	-11	-8	N/A
6/30/2018	161	-4	N/A	-6	N/A
3/31/2018	141	-10	N/A	-13	N/A
12/31/2017	133	-11	N/A	-4	N/A
9/30/2017	118	-16	N/A	-12	N/A
6/30/2017	108	-23	N/A	-36	N/A
3/31/2017	90	-28	N/A	-37	N/A
12/31/2016	83	-31	N/A	-45	N/A
9/30/2016	74	-33	N/A	-40	N/A
6/30/2016	70	-32	N/A	-31	N/A
3/31/2016	73	-27	N/A	-27	N/A
12/31/2015	73	-21	N/A	-23	N/A
9/30/2015	73	-20	N/A	-19	N/A
6/30/2015	66	-16	N/A	-19	N/A
3/31/2015	62	-8	N/A	-14	N/A
12/31/2014	57	-7	N/A	-13	N/A
9/30/2014	56	-5	N/A	-8	N/A
6/30/2014	59	-4	N/A	-12	N/A
3/31/2014	52	-17	N/A	-29	N/A
12/31/2013	49	-21	N/A	-23	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 0R44の予測収益成長率 (年間34.7% ) は貯蓄率 ( 2.1% ) を上回っています。

収益対市場: 0R44の収益 ( 34.7% ) はUK市場 ( 14.6% ) よりも速いペースで成長すると予測されています。

高成長収益: 0R44の収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: 0R44の収益 ( 14.8% ) UK市場 ( 3.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: 0R44の収益 ( 14.8% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 0R44の自己資本利益率は、3年後には高くなると予測されています ( 24.5 %)

C-Rad 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Recent updates

C-Rad AB (publ) to Report Q3, 2025 Results on Oct 23, 2025

Independent Director recently bought kr190k worth of stock

New minor risk - Market cap size

Third quarter 2024 earnings released: EPS: kr0.45 (vs kr0.32 in 3Q 2023)

CEO & President recently bought kr85k worth of stock

Second quarter 2024 earnings released: EPS: kr0.31 (vs kr0.16 in 2Q 2023)

Full year 2023 earnings released: EPS: kr1.05 (vs kr0.22 in FY 2022)

C-Rad AB (publ) Appoints Mats Thorén as Board Member

C-Rad AB (publ) to Report Fiscal Year 2023 Results on Apr 23, 2024

Full year 2023 earnings released: EPS: kr1.36 (vs kr0.22 in FY 2022)

C-Rad AB (publ) to Report Q3, 2024 Results on Oct 23, 2024

Third quarter 2023 earnings released

Investor sentiment improves as stock rises 17%

Less than half of directors are independent

C-Rad AB (Publ) Announces Former Employee Appeals Verdict from the Patent and Market Court of Appeal

New major risk - Earnings quality

C-Rad AB (publ) to Demonstrate Enhancements in Surface Guided Solutions for Advanced Radiotherapy Treatments at AAPM

Second quarter 2023 earnings released

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

C-Rad AB (publ) to Report Fiscal Year 2022 Final Results on Apr 06, 2023

C-Rad AB (Publ) Appoints Christoffer Herou as CFO

C-Rad AB (Publ) Announces CEO Changes

C-Rad AB (publ) Announces CFO Changes

C-Rad AB (publ) to Report Q3, 2023 Results on Oct 27, 2023

C-RAD Launches New Updated eDucation Portal as an Online Platform

Second quarter 2022 earnings released

Henrik Bergentoft Resigns as CFO of C-RAD

C-Rad Announces CEO Changes

Insufficient new directors

Insufficient new directors

C-Rad AB (publ) to Report Q3, 2022 Results on Oct 28, 2022

C-Rad Achieves Another Milestone Ensuring the Availability of SGRT, the Standard of Care for Radiotherapy

Third quarter 2021 earnings released

Chief Operating Officer recently sold kr625k worth of stock

Second quarter 2021 earnings released

C-Rad AB (publ) Announces The Patent and Market Court Rejected Former Employee Claim for Compensation

The Patent and Market Court of Appeal Issues Judgement Confirming C-Rad's Entitlement to Beamocular's Invention

Full year 2020 earnings released: EPS kr0.43 (vs kr0.45 loss in FY 2019)

C-RAD and Alliance Radiation Oncology Announce That Alliance Has Become the First Center in the Greater Northshore Area to Integrate C-Rad

C-Rad and With-Global Engages in a Partnership for the South Korean Market

C-RAD Receives Order for Proton Cancer Treatment Centers in the US

Shenzhen Proton Therapy Treatment Center Selects C-Rad Catalyst™ System

C-Rad AB (publ) to Report Q2, 2021 Results on Jul 29, 2021

Shanghai Proton and Heavy Ion Hospital Decides for C-Rad Sigrt Solution

Australian Customers Select C-RAD’s Cutting Edge SIGRT Solution

C-Rad AB Receives SEK 11 Million Order for Cutting Edge SIGRT Solution by DTZ in Berlin

Independent Director recently sold kr672.4k worth of stock

Independent Director recently bought kr1.7m worth of stock

Independent Director recently sold kr3.4m worth of stock

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘